Shares of Nabriva Therapeutics PLC – (NASDAQ:NBRV) have earned a consensus recommendation of “Buy” from the ten brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $11.60.

Several brokerages have recently weighed in on NBRV. Zacks Investment Research raised Nabriva Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a report on Wednesday, August 1st. BidaskClub lowered Nabriva Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 24th. SunTrust Banks decreased their price objective on Nabriva Therapeutics to $11.00 and set a “buy” rating on the stock in a report on Wednesday, November 14th. Needham & Company LLC set a $18.00 price objective on Nabriva Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 9th. Finally, Morgan Stanley started coverage on Nabriva Therapeutics in a research note on Friday, September 7th. They issued an “overweight” rating and a $8.00 price target on the stock.

Shares of NASDAQ:NBRV opened at $1.93 on Monday. Nabriva Therapeutics has a 1-year low of $1.84 and a 1-year high of $6.94. The company has a current ratio of 7.35, a quick ratio of 7.35 and a debt-to-equity ratio of 0.01.

A number of hedge funds have recently made changes to their positions in the stock. Vivo Capital LLC boosted its stake in Nabriva Therapeutics by 62.5% in the 3rd quarter. Vivo Capital LLC now owns 6,619,190 shares of the biotechnology company’s stock valued at $17,872,000 after buying an additional 2,545,000 shares in the last quarter. BlackRock Inc. boosted its stake in Nabriva Therapeutics by 99.5% in the 3rd quarter. BlackRock Inc. now owns 936,624 shares of the biotechnology company’s stock valued at $2,529,000 after buying an additional 467,119 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Nabriva Therapeutics by 74.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 600,393 shares of the biotechnology company’s stock valued at $1,621,000 after buying an additional 256,332 shares in the last quarter. Prosight Management LP boosted its stake in Nabriva Therapeutics by 73.6% in the 2nd quarter. Prosight Management LP now owns 421,414 shares of the biotechnology company’s stock valued at $1,467,000 after buying an additional 178,725 shares in the last quarter. Finally, Laurion Capital Management LP acquired a new stake in Nabriva Therapeutics in the 3rd quarter valued at $1,133,000. 3.90% of the stock is currently owned by institutional investors and hedge funds.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

See Also: What is a Market Correction?

Analyst Recommendations for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.